Guidance, NICE advice and quality standards In development
Showing 376 to 381 of 381
| Title | Type | Expected publication date |
|---|---|---|
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | TBC |
| Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | |
| Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
| Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] | Technology appraisal guidance |